310, 311 (2015) (analyzing "the extent to which JMP-led post-2015 and GLAAS
data sources could contribute to monitoring HRWS [human right to water and sanitation] in a broad sense").
Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, has used the GLAAS
discovery platform in the Phase 1 clinical trial of MEDI7510, it was reported yesterday.
M2 PHARMA-May 29, 2014-Immune Design uses GLAAS
discovery platform in Phase 1 clinical trial of MEDI7510
At the same time, Immune Design would offer a specific formulation of GLA from the GLAAS
platform at its cost through Phase II studies.